上海医药西格列汀二甲双胍缓释片获批生产

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of its Sitagliptin Metformin Extended-Release Tablets, which are intended for adult patients with type 2 diabetes who are undergoing combined treatment with Sitagliptin and Metformin [1] Group 1 - The approved drug is specifically designed for adult patients with type 2 diabetes [1] - The drug was originally developed by Merck Sharp & Dohme and was launched in the United States in 2012 [1]